Back to products

Xpovio 20 mg Tablet

Brand Name: Xpovio

Molecule: Selinexor

Strength: 20 mg

Quantity: 16 Tablets

Form: Tablet

Packaging Type: Bottle

Manufacturer/Marketed By: Karyopharm Therapeutics

Country of Origin: USA

Image	Product	Manufacturer / Marketed By	Price
	LuciSelin 20 mg Tablet	Lucius Pharma	Ask for Price
	Selinex 20 mg Tablet	Everest Pharma	Ask for Price

Description

Xpovio 20 mg Tablet contains selinexor, a targeted anticancer medicine classified as a selective inhibitor of nuclear export (SINE). It is used in the treatment of certain blood cancers, particularly multiple myeloma, and in some cases diffuse large B-cell lymphoma (DLBCL). Selinexor works by blocking a protein called exportin-1 (XPO1), which plays a role in transporting tumor suppressor proteins out of the cell nucleus. In many cancer cells, overactivity of exportin-1 can lead to reduced activity of tumor-suppressing proteins that help control abnormal cell growth. By inhibiting this transport mechanism, selinexor helps restore the activity of these proteins and may slow or stop cancer cell proliferation when used as prescribed by a qualified healthcare professional. Xpovio tablets are taken orally and are usually prescribed as part of combination therapy with other anticancer medicines

Benefits

Targets exportin-1 (XPO1), a protein involved in cancer cell survival
Represents a novel mechanism of action in cancer treatment
Oral tablet therapy that can be taken outside hospital settings
Often used in combination regimens for relapsed or refractory cancers
Part of modern targeted therapy approaches in hematologic oncology

Indications and Usage

Xpovio (selinexor) may be prescribed for:

Multiple myeloma, often in combination with other anticancer medicines
Relapsed or refractory multiple myeloma in patients who have received prior therapies
Diffuse large B-cell lymphoma (DLBCL) in certain treatment situations

Treatment decisions depend on disease type, prior treatments, and clinical evaluation.

How it Works

Selinexor works by inhibiting exportin-1 (XPO1), a nuclear export protein responsible for transporting certain regulatory proteins from the nucleus to the cytoplasm of the cell. In many cancer cells, XPO1 is overexpressed, which leads to the removal of tumor suppressor proteins from the nucleus, weakening their ability to control cell growth.

By blocking XPO1, selinexor helps retain tumor suppressor proteins within the cell nucleus, restoring their function in regulating cell division and promoting cancer cell death. This mechanism may help slow disease progression when the medicine is used as prescribed and monitored by an oncology specialist.

Dosage & Administration

Xpovio tablets are taken orally with water.
The medicine is usually taken once or twice weekly, depending on the treatment regimen prescribed by the healthcare professional.
Tablets should be swallowed whole and not crushed or chewed.
The medicine may be taken with or without food, unless directed otherwise.
Dose adjustments may be required depending on treatment tolerance and laboratory findings.

Side Effects

Common side effects

Nausea
Fatigue
Loss of appetite
Diarrhea
Low blood platelet counts (thrombocytopenia)
Weight loss

Serious side effects

Severe low blood cell counts
Serious infections
Severe nausea or vomiting
Hyponatremia (low sodium levels)
Neurological symptoms such as confusion or dizziness

Patients should seek medical attention if severe symptoms occur.

Warning and Precaution

Risk of severe thrombocytopenia (low platelet count)
Possible serious infections due to immune suppression
Risk of low sodium levels (hyponatremia)
Severe nausea, vomiting, or weight loss may occur
Monitor blood counts and electrolyte levels during treatment
Inform healthcare providers about all medications and supplements being used
Pregnancy should be avoided during therapy

Patient Guidance

Take the medicine exactly as prescribed by your oncologist
Attend scheduled blood tests and monitoring appointments
Report symptoms such as unusual bleeding, severe fatigue, or infections
Follow guidance on hydration and nutrition during treatment
Inform your doctor about all medications and supplements
Do not stop treatment without consulting your healthcare provider

Clinical Trial & Approvals

Selinexor has been studied in clinical trials evaluating treatment for relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma. Trials such as the STORM and BOSTON studies demonstrated clinical activity of selinexor-based regimens in certain patient populations. Based on these results, selinexor received approvals from regulatory authorities including the U.S. Food and Drug Administration (FDA) for specific oncology indications.

References

U.S. Food and Drug Administration (FDA) – Selinexor Prescribing Information
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212306s011lbl.pdf
European Medicines Agency (EMA) – Selinexor Product Information
https://www.ema.europa.eu
National Cancer Institute – Selinexor Drug Information
https://www.cancer.gov
Drugs.com – Selinexor Drug Information
https://www.drugs.com
ClinicalTrials.gov – Selinexor Clinical Studies
https://clinicaltrials.gov

Prescription & documentation note

Xpovio 20 mg Tablet is typically supplied against a valid prescription. For international orders, patients may need to provide documentation such as a licensed physician’s prescription, identification, and country-specific import documentation, depending on destination regulations. MedsMonk may assist with documentation guidance where applicable.

FAQ

What is Xpovio 20 mg Tablet used for?+

It is used to treat multiple myeloma and certain lymphomas, particularly in patients who have received prior treatments.

What is the active ingredient in Xpovio?+

The active ingredient is selinexor, a selective inhibitor of nuclear export.

Is Xpovio chemotherapy?+

Xpovio is considered a targeted therapy, not traditional chemotherapy.

How is Xpovio taken?+

It is usually taken once or twice weekly by mouth, depending on the treatment regimen.

What monitoring is required during treatment?+

Patients may require regular blood tests to monitor platelet counts, sodium levels, and overall health.

Can Xpovio be used alone?+

It is often used in combination with other cancer medicines, depending on the treatment plan.

Is a prescription required for Xpovio?+

Yes. Xpovio is a prescription-only oncology medicine.

How should Xpovio tablets be stored?+

Store at room temperature, away from moisture and excessive heat.

Bone Marrow Transplant: A Complete Guide for Patients

The realization that you or someone close to you needs a bone marrow transplant can be extremely daunting. It may

June 16, 2026

Ruxolitinib Tablets Receive FDA Approval for Hematologic Malignancies

The U.S. Food and Drug Administration (FDA) has approved Ruxolitinib tablets for the treatment of certain hematologic malignancies, marking another

May 18, 2026

Tovorafenib Approved in Europe for Children with BRAF-Altered Low-Grade Glioma

n Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 14, 2026.n n This marks an important

May 14, 2026

Rated 0 out of 5

0 reviews

Rated 5 out of 5

Rated 4 out of 5

Rated 3 out of 5

Rated 2 out of 5

Rated 1 out of 5

Reviews

Clear filters

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.